US 12,215,360 B2
Encapsulation of dual-enzyme composition for preventing, treating and/or alleviating veisalgia and symptoms associated therewith
Bing Lou Wong, San Diego, CA (US); Sek Lun Law, Hong Kong (HK); Joo Ann Ewe, Hong Kong (HK); and Chun Hay Ko, Hong Kong (HK)
Assigned to Bing Biotech Limited, Hong Kong (HK)
Filed by Bing Biotech Limited, Hong Kong (HK)
Filed on Sep. 12, 2023, as Appl. No. 18/465,961.
Application 18/465,961 is a continuation in part of application No. 17/947,195, filed on Sep. 19, 2022, granted, now 11,795,441.
Application 17/947,195 is a continuation in part of application No. 17/557,046, filed on Dec. 21, 2021, granted, now 11,471,514, issued on Oct. 18, 2022.
Application 17/557,046 is a continuation in part of application No. 17/308,995, filed on May 5, 2021, granted, now 11,208,631, issued on Dec. 28, 2021.
Prior Publication US 2024/0216479 A1, Jul. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/04 (2006.01); C12N 9/02 (2006.01); A61K 38/44 (2006.01)
CPC C12N 9/0006 (2013.01) [C12N 9/0008 (2013.01); C12Y 101/01001 (2013.01); A61K 38/44 (2013.01)] 12 Claims
OG exemplary drawing
 
1. An encapsulated composition for converting ethanol to acetaldehyde and subsequently converting the acetaldehyde to acetate, the composition comprising alcohol dehydrogenase and aldehyde dehydrogenase in a molar ratio of approximately 1:3 to approximately 1:51, the composition being encapsulated by a polysaccharide-whey-casein encapsulant such that the encapsulated composition is an orally-administered controlled release composition in the small intestine.